Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

By | November 1, 2021
A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response.